// App-Quantinova.ai

7570 : Sequence variants in patients with primary and acquired resistance to ibrutinib in the phase 3 MCL3001 (RAY) trial.

Researchers

Presenter

  • Georg Lenz

Principal Investigators

  • Sriram Balasubramanian

  • Jenna Goldberg

  • Aleksandra Rizo

  • Michael Schaffer

  • Charles Phelps

  • Simon Rule

  • Martin H. Dreyling

Medical Centers

  • Translational Oncology Medical Clinic, Munster University Clinic, Munster, Germany

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research & Development, LLC, Raritan, NJ

  • Department of Haematology, Derriford Hospital, Plymouth, United Kingdom

  • Department of Medicine III, University Hospital Grosshadern/LMU, Munich, Germany

Locations

  • United States

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Ibrutinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01646021

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved